Year: 2023

Positive initial data and clean safety profile catalyze optimization planSize of both ongoing clinical trials significantly increasedLower dose eliminated from blinded trialDosing frequency changed to twice-daily from once-daily for both trials ASHBURN, Va., Dec. 13, 2023 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has received U.S. Food and Drug Administration (FDA) clearance to implement a number of protocol amendments to its two ongoing clinical trials for QRX003, which is being developed as a potential treatment for Netherton Syndrome (NS). Both trials are being conducted under Quoin’s open Investigational New Drug Application (IND) for QRX003. “We are extremely pleased to announce clearance...

The Company is highlighting recent significant achievements to update new and existing investors prior to the holiday season. LAS VEGAS, Dec. 13, 2023 (GLOBE NEWSWIRE) — via IBN — GEMXX Corporation (OTC: GEMZ) (“GEMXX” or the “Company”), a leader in the ammolite gemstone mine-to-market segment and a partner in Canadian gold exploration Company Crazy Horse Mining, Inc. (“CHMI” or “Crazy Horse”) today provides the following updates: Current StateGEMXX has achieved significant milestones recently, and it’s worth noting that the Company continues to control each stage of its production, including gold mining, gemstone production, jewelry manufacturing and global distribution. Further, the Company continues to expand while avoiding long-term debt. Jay Maull, GEMXX CEO, said: “We are tremendously pleased with the development...

VISTA Blocking KVA12123 Monoclonal Antibody (mAb) Engineered to Provide Strong Single Agent Anti-Tumor Activity While Minimizing Cytokine Related Adverse Events KVA12123 recognizes a unique VISTA epitope and binds at neutral and acidic pH Data Supports KVA12123’s Potential as a Therapy Against Poorly Immunogenic Tumors SEATTLE, Dec. 13, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the peer-reviewed publication in Frontiers in Immunology of preclinical data highlighting the potential of KVA12123 as a new immunotherapy against poorly immunogenic tumors. The publication titled “A Highly Potent Anti-VISTA Antibody KVA12123 – A New Immune Checkpoint Inhibitor and a...

PLANO, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) — Stryve Foods, Inc. (“Stryve” or “the Company”) (NASDAQ: SNAX), a pioneer in healthy protein snacks, is excited to announce a strategic partnership with Acosta Group (“Acosta”), a prominent sales and marketing agency. The collaboration brings together the expertise and market reach of both companies, with a shared commitment to delivering high-quality products to consumers across the nation. Chris Boever, CEO of Stryve, expressed enthusiasm about the partnership, stating, “We are thrilled to join forces with Acosta Group. This collaboration aligns seamlessly with our vision to make healthy snacking accessible to a broader audience. Acosta’s proven track record in sales and marketing will undoubtedly enhance our market presence and accelerate the growth of our portfolio of...